Skoči na glavni sadržaj

Studija slučaja

https://doi.org/10.15644/asc57/1/7

Effect of Denosumab Therapy on Pain Level in Diffuse Sclerosing Osteomyelitis of the Mandible: a Case Report

Daniel Jerković ; Zavod za maksilofacijalnu kirurgiju Kliničkoga bolničkoga centra Split, Odjel za oralnu kirurgiju Medicinskoga fakulteta Sveučilišta u Splitu, Hrvatska
Kristian Jerković ; Klinički zavod za dijagnostičku i intervencijsku radiologiju Kliničkoga bolničkoga centra Split, Hrvatska
Antonella Lesin ; Zavod za maksilofacijalnu kirurgiju Kliničkoga bolničkoga centra Split, Odjel za oralnu kirurgiju Medicinskoga fakulteta Sveučilišta u Splitu, Hrvatska
Ana Poljičanin ; Zavod za fizikalnu medicinu i rehabilitaciju s reumatologijom Kliničkoga bolničkoga centra Split, Sveučilišni odjel zdravstvenih studija Sveučilišta u Splitu, Hrvatska
Ivan Galić ; Zavod za maksilofacijalnu kirurgiju Kliničkoga bolničkoga centra Split, Odjel za oralnu kirurgiju Medicinskoga fakulteta Sveučilišta u Splitu, Hrvatska


Puni tekst: engleski pdf 1.083 Kb

str. 62-69

preuzimanja: 539

citiraj

Puni tekst: hrvatski pdf 1.083 Kb

str. 62-69

preuzimanja: 238

citiraj


Sažetak

This is the first case report where two patients were under uniform denosumab administration protocol in diffuse sclerosing osteomyelitis (DSO) treatment and were closely monitored for 18 months. Objectives: This study aimed to describe the beneficial effects of denosumab in DSO treatment as well as pain relief and the significant lack of long-term use due to poorer outcomes after repeated use. DSO of the jaw is a poorly understood rare chronic disease the treatment of which is still very challenging despite a rapid development of medicine. Different medical treatments have been pro-posed without any significant long-lasting success. Bisphosphonates have offered substantial clinical benefit in DSO therapy, but due to harmful pharmacodynamic properties, denosumab therapy has been used to replace bisphosphonate therapy. Patients had a reduction in pain intensity with each subsequent application of denosumab but with less success than the first administration of de-nosumab. This case report has shown that denosumab could be a promising conservative treatment option for pain treatment in patients suffering from DSO.

Ključne riječi

Osteomyelitis; Mandible; Pain Management; Denosumab; Pain; Sclerosing Osteomyelitis; Oral Surgery

Hrčak ID:

296291

URI

https://hrcak.srce.hr/296291

Datum izdavanja:

27.3.2023.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.749 *